JP2011510008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510008A5 JP2011510008A5 JP2010543198A JP2010543198A JP2011510008A5 JP 2011510008 A5 JP2011510008 A5 JP 2011510008A5 JP 2010543198 A JP2010543198 A JP 2010543198A JP 2010543198 A JP2010543198 A JP 2010543198A JP 2011510008 A5 JP2011510008 A5 JP 2011510008A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pain
- construction
- disease
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 238000010276 construction Methods 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000004820 halides Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000036407 pain Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2215208P | 2008-01-18 | 2008-01-18 | |
| US61/022,152 | 2008-01-18 | ||
| PCT/US2009/030887 WO2009091760A1 (en) | 2008-01-18 | 2009-01-14 | Oxazolidine and thiazolidine selective subtype alpha 2 adrenergic agents and methods for use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510008A JP2011510008A (ja) | 2011-03-31 |
| JP2011510008A5 true JP2011510008A5 (https=) | 2012-03-01 |
| JP5583028B2 JP5583028B2 (ja) | 2014-09-03 |
Family
ID=40345009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543198A Expired - Fee Related JP5583028B2 (ja) | 2008-01-18 | 2009-01-14 | オキサゾリジン及びチアゾリジン選択的サブタイプアルファ２アドレナリン作用薬並びにこれらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8735399B2 (https=) |
| EP (1) | EP2242753B1 (https=) |
| JP (1) | JP5583028B2 (https=) |
| AU (1) | AU2009205473B8 (https=) |
| BR (1) | BRPI0906875A2 (https=) |
| CA (1) | CA2712190A1 (https=) |
| WO (1) | WO2009091760A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809379B2 (en) * | 2008-01-18 | 2014-08-19 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| AU2010289703A1 (en) * | 2009-08-26 | 2012-04-12 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2B adrenergic receptor agonists |
| HUE038366T2 (hu) | 2010-08-16 | 2018-10-29 | Allergan Inc | Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06006501A (es) | 2003-12-23 | 2006-08-23 | Basf Ag | Compuestos de 1-(azolin-2-il)amino-1,2-difeniletano para combatir insectos, aracnidos y nematodos. |
| CN101346374A (zh) * | 2005-12-22 | 2009-01-14 | 巴斯夫欧洲公司 | 农业组合物 |
| US7709507B2 (en) * | 2006-05-17 | 2010-05-04 | Allergan, Inc. | Therapeutic fluoroethyl ureas |
| WO2008123821A1 (en) * | 2007-03-01 | 2008-10-16 | Albireo Ab | 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders |
| US8809379B2 (en) * | 2008-01-18 | 2014-08-19 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| JP5480819B2 (ja) * | 2008-01-18 | 2014-04-23 | アラーガン インコーポレイテッド | 選択的サブタイプアルファ２アドレナリンアゴニスト及びその使用方法 |
-
2009
- 2009-01-14 EP EP09703035.7A patent/EP2242753B1/en not_active Not-in-force
- 2009-01-14 BR BRPI0906875-9A patent/BRPI0906875A2/pt not_active IP Right Cessation
- 2009-01-14 JP JP2010543198A patent/JP5583028B2/ja not_active Expired - Fee Related
- 2009-01-14 AU AU2009205473A patent/AU2009205473B8/en not_active Ceased
- 2009-01-14 CA CA2712190A patent/CA2712190A1/en not_active Abandoned
- 2009-01-14 WO PCT/US2009/030887 patent/WO2009091760A1/en not_active Ceased
- 2009-01-14 US US12/863,386 patent/US8735399B2/en active Active
-
2014
- 2014-03-20 US US14/220,823 patent/US20140206701A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522774A5 (https=) | ||
| JP2011509297A5 (https=) | ||
| JP2007516941A5 (https=) | ||
| JP2004517852A5 (https=) | ||
| JP2015531764A5 (https=) | ||
| JP2008526888A5 (https=) | ||
| JP2005527579A5 (https=) | ||
| CN1178935C (zh) | 用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷 | |
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| JP2006516977A5 (https=) | ||
| JP2014502982A5 (https=) | ||
| JP2011517443A5 (https=) | ||
| JP2011510008A5 (https=) | ||
| JP2009538867A5 (https=) | ||
| MA29353B1 (fr) | Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines | |
| JP2017524005A5 (https=) | ||
| BR112013024312A2 (pt) | derivados de amina heterocíclica | |
| JP2019525939A5 (https=) | ||
| JP2011518858A5 (https=) | ||
| AR070512A1 (es) | Derivados monoamina como antagonistas del receptor de orexina , proceso para la preparacion de dichos compuestos , medicamentos que los contienen y uso de los mismos | |
| JP2012526832A5 (https=) | ||
| JP2013523846A5 (https=) | ||
| JP2012508275A5 (https=) | ||
| JP2017509676A5 (https=) | ||
| CN1218461A (zh) | 烷氨基苯并噻唑及－苯并噁唑衍生物 |